Huadong Medicine has obtained approvals for three new products at the start of the year, which is nearly half of last year's total.|Quick read announcement.
① Huadong Medicine announced today that three products have received approval for market release, while a total of seven products were approved for market release last year; ② Among them, a hyaluronic acid product in the medical aesthetics category and a Chemical Drug for treating ovarian cancer received domestic approval, while a medical instrument for evaluating kidney function received approval in the USA; ③ Huadong Medicine believes that the approvals will not have a significant impact on the current financial condition and Operating results of the company.
Opening more new stores but struggling to make a profit, Yixintang Pharmaceutical's net income is expected to drop by over 70% last year | Interpretations
① Yixintang Pharmaceutical expects a Net income decline of 72.7%–81.8% in 2024 compared to the same period last year; ② The company stated that the performance variation is mainly due to the expansion of the company's stores leading to increased Operation costs, as well as some new and relatively new stores being in the initial loss stage.
6 popular stocks with 4 limit-ups in 6 days: A wholly-owned subsidiary plans to invest in the construction of a "new project" | Selected post-market announcements.
In 6 days, 4 hot stocks in the Robot Concept, the subsidiary plans to invest in the construction of a "new project," a leading financial IT company worth billions will change ownership, and the "number one" in PC security products is expected to have a Net income loss in the 2024 fiscal year...
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Breaking! This company and its actual controller have been investigated by the CSRC for suspected violations of information disclosure laws and regulations | Post-market announcement highlights.
Sufa Technology Industry: plans to acquire 71.965% equity of China Nuclear West Instruments, which is expected to constitute a significant asset restructuring.